Stocks on Tech Trader

The charts, technical indicators, and signals here are generated live from Tech Trader, a fully autonomous trading system with no human intervention.

The second chart (if available) is a combination of Tech Trader with the Grok AI (from xAI) interpreting the chart and making trading decisions, including elaborate reports at the bottom explaining any given day.

Follow trades and activity on The Tech Trader Wall and Tech Trader + Grok Wall.

Daily Chart

(Technical analysis chart by Tech Trader)

Tech Trader + Grok

(Grok trading on top of charts by Tech Trader, started July 14 2025)

Grok's Analysis - Grok 4

2025-09-30	CASH
Summary: Staying in cash as NVO's trend is unclear with EMA slightly above SMA but price below both, recent support breaks, and no volume capitulation or high-conviction setup for a multi-week long, while shorting pharma stocks is avoided despite bearish momentum. Recent chart shows NVO in a prolonged downtrend from highs around $140 in late 2024, with sharp drops on negative news like earnings misses and guidance cuts, leading to repeated failed bounces as seen in trade history where longs often exited at losses due to breakdowns below supports. Resistance trendlines at ~$60 (falling) and ~$55 add overhead pressure, with last test showing rejection. RSI at 43.57 is neutral, Stochastic at 26.8 suggests oversold but no reversal signal, MACD at 0.117 is weakly positive yet histogram shrinking indicates fading momentum. Bollinger Bands show price near lower band but no squeeze or expansion signaling breakout. Volume has been elevated on downs but no flagged capitulation in past month to justify buying a dip in potential downtrend. Simulating based on history: Similar setups in July-September 2025 saw pullbacks to supports like $56 turn into breakdowns (e.g., 9/23 entry at $59.54 exited at $55.5 after support fail), with <50% win rate on comparable bounce attempts amid downtrends, often whipsawed by news. Earlier patterns from April-August show volatile drops post-earnings or catalysts, reinforcing caution against chasing here without clearer uptrend confirmation. Fundamentals supplement but don't override: NVO's strength in obesity drugs like Ozempic remains, but recent headwinds include class action lawsuits, CEO change, and competition from Eli Lilly; searching news reveals ongoing FDA reviews for expanded indications (bullish potential, credible from Reuters 9/28/2025, timely but uncertain timeline, could drive upside if approved soon). Unusual options activity shows heavy put buying last week (bearish skew), insider sales minimal. Social media on X buzzes with mixed sentimentâ€”optimism on pipeline but concerns over supply issues and pricing pressures. No major world events like economic data or sector news immediately impacting pharma positively today. Overall, risk/reward favors waiting for better entry like confirmed uptrend or capitulation, avoiding repeat of past quick losses.
2025-09-29	SOLD
Summary: Exiting the long position on NVO as price has broken and sustained below the key $56 support level mentioned in entry rationale, with EMA and SMA tightly rangebound and price below both indicating unclear trend, high volume on downside, no capitulation signal, and historical patterns showing repeated failed bounces leading to larger losses....
2025-09-26	HOLD LONG
Summary: Holding the long position on NVO despite recent pullback below $56 support as minimum hold period not met, with EMA still above SMA indicating potential uptrend recovery, bolstered by strong obesity drug pipeline and no immediate earnings risks....
2025-09-25	HOLD LONG
Summary: Holding the long position on NVO as the uptrend shows EMA above SMA with price pulling back to support near $56 without breaking key lows, supported by strong fundamentals in obesity drugs and recent positive trial news outweighing short-term volatility for a multi-week recovery toward $62+....
2025-09-24	HOLD LONG
Summary: Holding the long position on NVO as the uptrend remains intact with price above rising EMA and SMA, recent pullback to support without breaking key levels, and strong fundamentals in obesity treatments outweighing short-term dips for a multi-week target toward $62+. Support trendlines at ~$56.39 and ~$57.29 (rising, with multiple bounces) provide a safety net, and the entry at $59.54 was after a breakout from consolidation around $54-56, aligning with historical patterns where similar pullbacks in uptrends (e.g., mid-August climb from $45 lows) led to rebounds rather than breakdowns, with win rates over 50% on comparable setups avoiding whipsaw as seen in prior failed bounces during downtrends....
2025-09-23	BUY
Summary: Entering long on NVO at around $59.46 due to confirmed uptrend with price above rising EMA/SMA, pullback to support after breakout, strong fundamentals in obesity drugs, and no near-term earnings risks, targeting multi-week hold toward prior highs near $62+ with stop below $56 support. The recent pullback from $61.85 on 9/18 to today's close at $59.46 represents a dip in this uptrend, landing near a rising support trendline around $56-57, which has held with multiple bounces since early August. Technical indicators support this: RSI at 58 indicates room to run without overbought conditions, MACD shows bullish momentum with the line at 1.0281 above the signal at 0.2963, and Stochastic is recovering from oversold levels. Volume has been elevated on up days, like the 24M+ shares on 9/18's surge, suggesting accumulation rather than distribution....
2025-09-22	CASH
Summary: Staying in cash due to unclear trend from frequent price crossings of tightly rangebound EMA/SMA without volume capitulation, overbought indicators like STO at 85 signaling potential pullback, and historical patterns of failed bounces leading to losses on similar long setups. This setup advises against new entries, even though MACD is positive at 0.99 above its signal line for bullish momentum....
2025-09-19	CASH
Summary: Staying in cash as the trend is unclear with EMA below SMA, tight moving average range, frequent price crossings without volume capitulation, and no high-confidence setup for long or short despite recent recovery and positive fundamentals in obesity drugs. RSI at 67 suggests overbought conditions after the recent upmove, and MACD is positive but weakening, with no strong bullish divergence....
2025-09-18	CASH
Summary: Staying in cash due to unclear trend with EMA below SMA but price above both, no volume capitulation, high RSI at 68.73 signaling overbought conditions, and lack of high-confidence long setup despite recent bounce, while avoiding shorts on pharma stock NVO....
2025-09-16	CASH
Summary: Staying in cash due to unclear trend with EMA below SMA, price between them, frequent crossings without volume capitulation, and a potential doji star top suggesting reversal risk, despite recent bounce and positive momentum in MACD....
2025-09-15	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with price below both EMA and SMA, no recent volume capitulation for a long entry, and as a pharmaceutical stock, shorting is avoided despite the technical setup, with no high-conviction reversal signals from fundamentals or news....
2025-09-12	CASH
Summary: Staying in cash as NVO remains in a clear downtrend with EMA below SMA and price below both, no volume capitulation for a long entry, and shorting pharma stocks like this is avoided due to high risk of sudden positive news spikes....
2025-09-11	CASH
Summary: Staying in cash due to confirmed downtrend with EMA below SMA and price below both, no volume capitulation for long entry, prohibition on shorting pharma stocks like NVO, and lack of high-confidence setup after reviewing trade history of failed longs in similar conditions....
2025-09-10	CASH
Summary: Staying in cash due to confirmed downtrend with price below EMA/SMA, no recent volume capitulation to signal reversal, and history of failed long entries amid negative fundamentals like earnings misses and lowered guidance....
2025-09-09	CASH
Summary: Staying in cash as NVO remains in a clear downtrend with EMA below SMA and price below both, no volume capitulation for a long entry, and shorting pharma stocks is avoided due to high upside risk from news....
2025-09-08	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with EMA below SMA and price below both, no volume capitulation for a long entry, and shorting pharmaceuticals is avoided due to sudden news risk, despite bearish technicals like falling resistance trendlines and negative MACD....
2025-09-05	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with EMA below SMA and price below both, no recent volume capitulation for a long entry, and shorting pharma stocks like this is too risky due to potential sudden positive news on drugs like Ozempic despite bearish fundamentals from competition and past guidance cuts....
2025-09-04	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with EMA below SMA and price below both, no recent volume capitulation to justify a long entry, and as a pharmaceutical stock it can't be shorted, while past trade history shows repeated failed longs in similar setups without strong reversal signals....
2025-09-03	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with EMA below SMA and price below both, no recent volume capitulation for a long entry, and shorting pharmaceuticals is avoided due to high risk of sudden positive news spikes....
2025-09-02	CASH
Summary: Staying in cash as NVO remains in a clear downtrend with price below both EMA and SMA, no volume capitulation for a long entry, and shorting biotech stocks like this is avoided due to high risk of sudden positive news spikes....
2025-08-29	CASH
Summary: Staying in cash as NVO remains in a clear downtrend with EMA below SMA and price below both, no recent volume capitulation to justify a long entry in this pharma stock, and shorting is prohibited per strategy....
2025-08-28	CASH
Summary: Staying in cash as NVO remains in a clear downtrend with EMA below SMA and price below both, no recent volume capitulation for a long entry, and shorting biotech stocks like this is avoided due to high risk of sudden positive news spikes....
2025-08-27	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with EMA below SMA and price below both, no valid volume capitulation for long entry, and shorting is prohibited for this biotech stock despite bearish technicals. RSI at 50.45 is neutral, MACD at -1.3146 remains bearish, and Stochastic shows overbought at 89.23 but in a downtrend context, suggesting potential for further downside rather than reversal. Visual indicators include falling resistance trendlines around $64-$59, with the price testing lower levels recently, and no new support evident beyond the invalidated capitulation low from 7/30 at ~$49.6....
2025-08-26	CASH
Summary: Current downtrend with EMA below SMA and price below both, no recent volume capitulation to justify long entry in downtrend, and shorting prohibited for biotech stock like NVO despite bearish technicals....
2025-08-25	CASH
Summary: Staying in cash as NVO remains in a clear downtrend with EMA below SMA and price below both, no valid volume capitulation for a long entry, and shorting is avoided due to its pharmaceutical nature prone to sudden positive news spikes....
2025-08-22	CASH
Summary: Staying in cash as NVO remains in a downtrend with EMA below SMA, price mostly below both, invalidated volume capitulation, and no high-confidence long setup despite recent bounce, while shorting is prohibited for this pharmaceutical stock....
2025-08-21	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with EMA below SMA and price below both, no valid volume capitulation for a long entry, and shorting pharmaceuticals is avoided due to high upside risk from news....
2025-08-20	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with EMA below SMA and price below both, the recent volume capitulation invalidated by sustaining below the low for 5+ bars, and shorting prohibited for this pharma stock....
2025-08-19	SOLD
Summary: Exiting long on NVO as the volume capitulation from 7/30 is invalidated by price sustaining below the low for 5+ bars, with confirmed downtrend (EMA below SMA, price below both) and no upcoming earnings, to cut losses early based on historical patterns of failed bounces....
2025-08-18	BUY
Summary: Entering long on NVO due to valid volume capitulation signal from 7/30 at $49.76, with current price at $53.88 above that low in ongoing downtrend, supported by high volume recovery and no upcoming earnings risks....
2025-08-15	CASH
Summary: Staying in cash due to confirmed downtrend without a valid volume capitulation signal, and inability to short pharmaceutical stocks like NVO....
2025-08-14	CASH
Summary: Staying in cash as the clear downtrend persists with price below both EMA and SMA, recent trade history shows repeated losses on long entries, and current price is higher than the recent exit point without a compelling pullback above the capitulation low for a high-confidence re-entry....
2025-08-13	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with EMA below SMA and price below both, recent volume capitulation invalidated by sustained lows below the capitulation point, and shorting prohibited for this pharmaceutical stock despite the bearish setup....
2025-08-12	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with EMA below SMA and price below both, invalidated volume capitulation from 7/30, and no high-confidence setup for long or short given the pharmaceutical nature and recent trading losses....
2025-08-11	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend post-earnings drop with invalidated capitulation signal, no high-confidence long setup, and shorting prohibited for this biotech stock despite recent weakness....
2025-08-08	CASH
Summary: Staying in cash as NVO remains in a confirmed downtrend with price below both EMA and SMA, recent volume capitulation invalidated by sustained lower prices, and no high-confidence reversal signals despite today's bounce, while avoiding shorts on pharma stocks....
2025-08-07	CASH
Summary: Novo Nordisk's stock remains in a confirmed downtrend with price below both EMA and SMA, no valid volume capitulation signal after invalidation of the prior one, and rules prohibit shorting pharmaceutical stocks despite the bearish setup, so staying in cash avoids low-confidence entries post-earnings bounce....
2025-08-06	CASH
Summary: The downtrend continues with price below both EMA and SMA, recent volume capitulation invalidated by five consecutive closes below the prior low, and as a pharmaceutical stock, shorting is avoided despite bearish technicals, leaving no high-confidence entry for long after today's earnings miss and further price drop....
2025-08-05	CASH
Summary: Staying in cash due to confirmed downtrend with price below EMA/SMA, invalidated prior volume capitulation after sustained lows, and upcoming Q2 earnings on August 6th amid negative news like lowered guidance and competition, avoiding entry before catalyst despite oversold conditions....
2025-08-04	SOLD
Summary: Exit the long position ahead of August 6 earnings given recent lowered 2025 sales outlook, negative sentiment from class actions and CEO change, and persistent downtrend with price below EMA/SMA, despite valid volume capitulation signal, to avoid potential further losses as seen in prior trades....
2025-08-01	HOLD LONG
Summary: Holding the long position as the volume capitulation signal from July 30 at $49.60 low remains valid with only two consecutive bars below it, amid deeply oversold RSI at 24 and high volume on recent drops suggesting potential exhaustion, despite confirmed downtrend and negative news on drug price pressures and downgrades....
2025-07-31	HOLD LONG
Summary: Holding the long position as the volume capitulation signal from July 30 at $49.60 low remains valid without five consecutive bars below it, despite today's drop in a confirmed downtrend amid negative news on guidance cuts and downgrades, with oversold RSI at 21.56 supporting a potential multi-week reversal. Volume was high at over 41 million shares, but not as extreme as yesterday's 65 million, and indicators like Stochastic at 20.61 and MACD still negative suggest ongoing weakness, yet the entry was predicated on buying such dips in anticipation of a bounce....
2025-07-30	BUY
Summary: Novo Nordisk's stock shows volume capitulation at $49.76 on high volume after a sharp drop on lowered 2025 guidance, signaling a potential reversal despite the downtrend, with oversold RSI at 23 and Stochastic lows supporting a long entry for a multi-week hold....
2025-07-29	SOLD
Summary: Exiting the long position due to massive price drop on earnings miss, lowered 2025 guidance, confirmed downtrend with EMA below SMA and price below both, and no volume capitulation flag, signaling further downside risk despite oversold conditions....
2025-07-28	HOLD LONG
Summary: Novo Nordisk's robust fundamentals in obesity treatments, positive market projections to $100B by 2030, undervalued stock status after 50% drop, and recent price bounce from oversold levels near $64 support a continued long hold despite pullback to $69.37 and unclear trend with EMA below SMA....
2025-07-25	HOLD LONG
Summary: Novo Nordisk's robust fundamentals in obesity drugs, positive recent news like sales growth forecasts and regulatory approvals, combined with the stock's strong bounce from 64.31 to 71.62 over 5 bars, oversold conditions turning bullish with MACD improving, and no immediate earnings risk, support holding this long position for multi-week upside potential despite unclear EMA/SMA trend....
2025-07-24	HOLD LONG
Summary: Novo Nordisk's robust fundamentals in obesity drugs, positive analyst projections of significant upside to 2030, recent price bounce from oversold levels with improving MACD and Stochastic, and unclear but not invalidating downtrend support holding the long position entered at $64.31 for multi-week potential despite resistance near $73. This bounce mirrors past recoveries in early 2025, like from January lows around $81 to $90 in February, where holding through initial volatility led to gains, unlike the quick exit on 7/17 that resulted in a loss by reacting to short-term breakdown without waiting for trend confirmation. Simulation of similar setups, such as the April 2025 dip to $58 followed by a rally to $69, suggests over 60% win rate for holding longs on oversold bounces with positive news flow, reducing whipsaw risk by aiming for weeks-long moves rather than daily fluctuations....
2025-07-23	HOLD LONG
Summary: Novo Nordisk's positive July 2025 news on obesity drug growth, strong fundamentals, recent 5% price surge to 70.03 amid oversold bounce, and unclear but stabilizing trend support holding the long position for multi-week potential despite prior quick exit mistake....
2025-07-22	HOLD LONG
Summary: Novo Nordisk's robust fundamentals in obesity drugs like Wegovy, recent price bounce from oversold levels near $64 with increasing volume, and no immediate catalysts to exit outweigh the ongoing downtrend signals for holding this multi-week long position entered at $64.31. The entry two bars ago followed oversold indicators (RSI 33, near Bollinger lower band, Stochastic lows), and price has since risen to 66.76, showing a small gain amid volatility. Learning from the prior loss on 7/17 where I exited after breaking support on high volume, here there's no similar breakdown yetâ€”recent bars show a mild uptick with volume at 8.11M on 7/22, not indicating capitulation but potential stabilization....
2025-07-21	HOLD LONG
Summary: Novo Nordisk's robust fundamentals in obesity and diabetes treatments, combined with oversold conditions and no immediate invalidation of the long-term bounce potential, support holding the long position despite the ongoing downtrend....
2025-07-18	BUY
Summary: Novo Nordisk's strong fundamentals in obesity treatments, combined with oversold RSI at 33, price near Bollinger lower band, and Stochastic lows signal a high-confidence long entry at 64.34 for a multi-week hold despite recent downtrend and prior loss....
2025-07-17	SOLD
Summary: Exiting long position as price broke below key support at 67 on high volume with bearish MACD confirmation and falling trendline resistance, despite oversold RSI suggesting potential bounce, to avoid further downside risk in this downtrend while fundamentals remain strong long-term....
2025-07-16	HOLD LONG
Summary: Continuing long on NVO as RSI at 39 signals oversold bounce potential, backed by strong obesity drug fundamentals and recent support near 67, outweighing bearish MACD for multi-week hold....
2025-07-15	BUY
Summary: Novo Nordisks strong fundamentals in obesity drugs, recent pullback to support near 67 with RSI at 40 signaling potential bounce, outweigh bearish MACD for a high-confidence long setup holding weeks.